Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Survival: 14.0 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: New York, NY
Hospital: Memorial Sloan-Kettering Cancer Center
Journal: Link
Date: 6/2008

Patients: This study involved 14 patients with metastatic renal cell carcinoma (kidney cancer). The median age was 70, ranging from 43 to 78 years. Most (86%) had previously been treated with surgery (nephrectomy).

Treatment: Patients were treated with the biological/immunological therapy lenalidomide, which is similar to thalidomide.

Toxicities: Grade 3 fatigue, hyperglycemia, and dyspnea were reported. Grade 4 hyperglycemia was also reported.

Results: The median overall survival was 14 months.

Support: This study was supported by research funds from Celgene, Inc., which markets lenalidomide as Revlimidô.

Correspondence: Dr. Robert J. Motzer

E-mail to a Friend Email Physician More Information